Think AHEAD of Alzheimer's Disease
Join a new Alzheimer’s prevention trial funded by NIH and Eisai Inc. testing an investigational treatment aimed at delaying memory decline in people before the symptoms of Alzheimer’s disease are apparent.
The AHEAD Study is an exciting, new development in Alzheimer’s disease research.
The AHEAD Study tests whether an investigational treatment slows the earliest brain changes associated with Alzheimer’s disease.
Brain changes related to Alzheimer’s disease can begin up to 20 years before a person exhibits symptoms.
Discovering a treatment that targets these changes early, means we may be able to some day prevent memory loss. The AHEAD Study tests whether an investigational treatment slows the earliest brain changes associated with Alzheimer’s disease.
Some participants will take part in the first pre-preclinical Alzheimer’s disease trial, representing a big step forward in Alzheimer’s disease research.
The AHEAD Study is breaking new ground in the field of Alzheimer’s research.
The AHEAD Study seeks cognitively normal adults ages 55-80 who may be at increased risk of memory loss associated with Alzheimer’s disease. This is the first Alzheimer’s disease prevention trial to enroll people as young as 55 years old.
Take the pre-screener to see if you are eligible to participate in the AHEAD Study.
There are many reasons to partner with the AHEAD Study researchers and join the fight against Alzheimer’s disease.
Think AHEAD of Alzheimer’s Disease
Participating in this research will help our understanding of how Alzheimer’s disease develops in the brain before symptoms appear, and hopefully contribute to finding a treatment to one day prevent memory loss due to Alzheimer’s disease.